Cardiovascular toxicity of novel psychoactive drugs: Lessons from the past

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 2, 2012, Pages 244-252

  Dawson, Patrick ^a   Moffatt, James D ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cardiovascular system; Drug abuse; Hallucinogen; Morbidity; Mortality; Stimulant

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; ATOMOXETINE; BENZYLPIPERAZINE; BROMO BENZODIFURANYLISOPROPYLAMINE; CANNABIS; COCAINE; DOPAMINE; EPHEDRINE; ERGOMETRINE; FENFLURAMINE; KETANSERIN; LISURIDE; LYSERGIDE; METHAMPHETAMINE; METHYLERGOMETRINE; METHYSERGIDE; N,N DIISOPROPYL 5 METHOXYTRYPTAMINE; NORADRENALIN; NOVEL PSYCHOACTIVE SUBSTANCE; PERGOLIDE; PIPERAZINE DERIVATIVE; PSEUDOEPHEDRINE; PSYCHOTROPIC AGENT; SEROTONIN; SEROTONIN AGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; CARDIOTOXICITY; CARDIOVASCULAR TOXICITY; COMA; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; GANGRENE; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPERTHERMIA; HYPOTENSION; INSOMNIA; LEG ISCHEMIA; MIGRAINE; NONHUMAN; PSYCHOSIS; REVIEW; RHINITIS; SHOCK; SIDE EFFECT; SYMPATHETIC TONE; THORAX PAIN; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; VASOCONSTRICTION;

ADRENERGIC AGONISTS; ANIMALS; CARDIOVASCULAR DISEASES; DOPAMINE AGONISTS; HUMANS; SEROTONIN RECEPTOR AGONISTS; STREET DRUGS;

EID: 84866998018     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.05.003     Document Type: Review

References (124)

1. Al-Motarreb A., Al-Habori M., Broadley K.J. Khat chewing, cardiovascular diseases and other internal medical problems: the current situation and directions for future research. J Ethnopharmacol 2010, 132:540-548.
2. Al-Motarreb A., Braincon S., Al-Jaber N., Al-Adhi B., Al-Jailani F., Salek M.S., et al. Khat chewing is a risk factor for acute myocardial infarction: a case control study. Br J Clin Pharmacol 2005, 59:574-581.
3. Abbas A., Roth B.L. Arresting serotonin. Proc Natl Acad Sci USA 2008, 105:831-832.
4. Abrahamson H.A., Rolo A. Lysergic acid diethylamide (LSD-25): XXXVIII. Comparison with action of methysergide and psilocybin on test subjects. J Asthma Res 1965, 3:81-96.
5. 1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 1993, 90:408-412.
6. Akay S., Ozdemir M. Acute coronary syndrome presenting after pseudoephedrine use and regression with beta-blocker therapy. J Cardiol 2008, 24:e86-e88.
7. Altura B.T., Altura B.M. Phencyclidine, lysergic acid diethylamide, and mescaline: cerebral artery spasms and hallucinogenic activity. Science 1981, 212:1051-1052.
8. Ambrose J.B., Bennet H.D., Lee H.S., Josephson S.A. Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion. Neurologist 2010, 16:199-202.
9. Andreasen M.F., Telving R., Birkler R.I.D., Schumacher B., Johannsen M. A fatal poisoning involving bromo-dragonfly. Forensic Sci Int 2009, 183:91-96.
10. Arbo M.D., Bastos M.L., Carmo H.F. Piperazine compounds as drugs of abuse. Drug Alcohol Depend 2012, 122:174-185.
11. Basket T.F. A flux of the reds: evolution of active management of the third stage of labour. J R Soc Med 2000, 93:489-493.
12. Basket T.F. The development of oxytocic drugs in the management of postpartum haemorrhage. Ulster Med J 2004, (Suppl.2-6).
13. Batman A.M., Dutta A.K., Reith M.E.A., Beardsley P.M. The selective dopamine uptake inhibitor, D-84, suppresses cocaine self-administration, but does not occasion cocaine-like levels of generalization. Eur J Pharmacol 2010, 648:127-132.
14. Baumann M.H., Ayestas M.A., Partilla J.S., Sink J.R., Shulgin A.T., Daley P.F., et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neurospsychopharmacology 2011, 37:1192-1203.
15. Baumann M.H., Clark R.D., Budzynski A.G., Partilla J.S., Blough B.E., Rothman R.B. Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain. Ann N Y Acad Sci 2004, 1025:189-197.
16. Bharatula A., New P.W. Cough mixture dependence and stroke: implications for pseudoephedrine regulation. Med J Aust 2011, 194:427.
17. Bhattacharyya S., Schapira A.H., Mikhailidis D.P., Davar J. Drug-induced fibrotic valvular heart disease. Lancet 2009, 374:577-585.
18. Bigal M.E., Golden W., Buse D., Chen Y.-T., Lipton R.B. Triptan use as a function of cardiovascular risk. A population-based study. Headache 2009, 50:256-263.
19. Blaho K., Merigian K., Winberry S., Geraci S.A., Smartt C. Clinical pharmacology of lysergic acid diethylamide: case reports and review of the treatment of intoxication. Am J Ther 1997, 4:211-221.
20. Carhart-Harris R.L., King D.A., Nutt D.J. A web-based survey on mephedrone. Drug Alcohol Depend 2011, 118:19-22.
21. Caudevilla-Galligo F., Riba J., Ventura M., Gonzalez D., Farré M., Barbanoi M.J., et al. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. J Psychopharmacol 2012, [Electronic publication ahead of print, Jan 9]. http://dx.doi.org/10.1177/0269881111431752.
22. Celik A. ST elevation myocardial infarction presenting after use of pseudoephedrine. Cardiovasc Toxicol 2009, 9:103-104.
23. Chen K.K., Schmidt C.F. The action of ephedrine, the active principle of the Chinese drug Ma Huang. J Pharmacol Exp Ther 1924, 24:339-357.
24. Christopherson J.B., Broadbent M. Ephedrine and pseudo-ephedrine in asthma, bronchial asthma, and enuresis. Brit Med J 1934, 1(3830):978-979.
25. Cruickshank C.C., Dyer K.R. A review of the clinical pharmacology of methamphetamine. Addiction 2009, 104:1085-1099.
26. 1C receptors. Trends Pharmacol Sci 1990, 11:181-182.
27. 2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol 2008, 594:32-38.
28. De Paoli G., Brandt S.D., Pounder D.J. Banned but still available on the internet. BMJ 2011, 342:614.
29. Davidson C., Ramsey J. Desoxypipradrol is more potent than cocaine on evoked dopamine efflux in the nucleus accumbens. J Psychopharmacol 2012, [Electronic publication ahead of print, Dec 7, 2011]. http://dx.doi.org/10.1177/0269881111430733.
30. Davies S., Wood D.M., Smith G., Button J., Ramsey J., Archer R., et al. Purchasing 'legal highs' on the Internet - is there consistency in what you get?. Q J Med 2010, 103:489-493.
31. Degenhardt L., Hall W. Addiction I: extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2011, 379:55-70.
32. Dowd J., Bailey D., Moussa K., Nair S., Doyle R., Culpepper-Morgan J.A. Ischemic colitis associated with pseudoephedrine: four cases. Am J Gastroenterol 1999, 94:2430-2434.
33. Edvinsson L., Hardebro J.E., Owman C. Pharmacological analysis of 5-hydroxytryptamine receptors in isolated intracranial and extracranial vessels of cat and man. Circ Res 1978, 42:143-151.
34. Eriksson E., Engberg G., Bing O., Nissbrandt H. Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 1999, 20:287-296.
35. European Monitoring Centre for Drugs and Drug Addiction Annual report on the state of the drugs problem in Europe. Lisbon, Portugal 2011.
36. Fantegrossi W.E., Harrington A.W., Kiessel C.L., Ecker J.R., Rabin R.A., Winter J.C., et al. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav 2006, 83:122-129.
37. 2A agonist TCB-2: a behavioural and neurophysiological analysis. Psychopharmacology 2010, 212:13-25.
38. Fysh R.R., Oon M.C.H., Robinson K.N., Smith R.N., White P.C., Whitehouse M.J. A fatal poisoning with LSD. Forensic Sci Int 1985, 28:109-113.
39. Giroud C., Augsburger M., Rivier L., Mangin P. 2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market. J Anal Toxicol 1998, 22:345-354.
40. Goldstein D.S. Catecholamines 101. Clin Auton Res 2010, 20:331-352.
41. Green A.R., Mechan A.O., Elliot J.M., O'Shea E., Coladao I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev 2003, 55:463-508.
42. Green A.R. Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK. Br J Pharmacol 2008, 154:1583-1599.
43. Greene S.L., Kerr F., Braitberg G. Amphetamines and related drugs of abuse. Emerg Med Australas 2008, 20:391-402.
44. Grześk G., Polak G., Grabczewska Z., Kubica J. Myocardial infarction with normal arteriogram: the role of ephedrine-like alkaloids. Med Sci Monit 2004, 10:CS12-CS15.
45. Glauser J., Queen J.R. An overview of non-cardiac toxicity. J Emerg Med 2007, 32:181-186.
46. Habel L.A., Cooper W.O., Sox C.M., Chan K.A., Fireman B.H., Arbogast P.G., et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011, 306:2673-2683.
47. Haarmann T., Rolke Y., Biesbert S., Tudzynski P. Ergot: from witchcraft to biotechnology. Mol Plant Pathol 2009, 10:563-577.
48. Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Allen S.C., Andrenyak D.M., et al. 4-Methylcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011, 339:530-536.
49. Halberstadt A.L., Geyer M.A. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 2011, 61:364-381.
50. Haller C.A., Benowitz N.L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000, 343:1833-1838.
51. Hallas J., Bjerrum L., Støvring H., Anderson M. Use of a prescribed ephedrine/caffeine as combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Am J Cardiol 2008, 168:966-973.
52. Heil S.H., Holmes H.W., Bickel W.K., Higgins S.T., Badger G.J., Laws H.F., et al. Comparison of subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002, 67:149-156.
53. Herridge C.F., A'Brook M.F. Ephedrine psychosis. Br Med J 1968, 2(5598):160.
54. Henry J.A. Management of drug abuse emergencies. J Accid Emerg Med 1996, 13:370-372.
55. Hill S.L., Thomas S.H.L. Clinical toxicology of newer recreational drugs. Clin Toxicol 2011, 49:705-719.
56. 2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 2006, 29:80-86.
57. Hutcheson J.D., Setola V., Roth B.L., Merryman W.D. Serotonin receptors and heart valve disease - it was meant 2B. Pharmacol Ther 2011, 132:146-157.
58. Ibrahim S.M., Mustafa E., Louon A. Postpartum severe sinus bradycardia following methylergonovine administration. J Int Med Res 2008, 36:1129-1133.
59. Lucki I., Ward H.R., Frazer A. Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. J Pharmacol Exp Ther 1989, 249:155-164.
60. Kaumann A.J., Levy F.A. 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 2006, 111:674-706.
61. Kaye S., McKetin R., Duflou J., Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007, 102:1204-1211.
62. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., et al. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 2011, 164:1949-1958.
63. Klock J.C., Boener U., Becker C.E. Coma and hyperthermia and bleeding associated with massive LSD overdose. West J Med 1973, 120:183-188.
64. Kloner R.A., Hale S., Alker K., Rezkalla S. The effects of acute and chronic cocaine use on the heart. Circulation 1992, 85:407-419.
65. Kobayashi S., Endou M., Sakuraya F., Matsuda N., Zhang X.-H., Azuma M., et al. The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release?. Anesth Analg 2003, 97:1239-1245.
66. Lange R.A., Cigarroa J.E., Hillis L.D. Cardiovascular complications of cocaine abuse. Trans Am Clin Climatol Assoc 2004, 115:99-114.
67. Lange R.A., Hillis L.D. Cardiovascular complications of cocaine use. N Engl J Med 2001, 345:351-358.
68. Liles J.T., Dabisch P.A., Hude K.E., Pradhan L., Varner K.J., Porter J.R., et al. Pressor responses to ephedrine are mediated by a direct mechanism in the rat. J Pharm Exp Ther 2006, 316:95-105.
69. Lobos M., Borges Y., Gonzalez E., Cassels B.K. The action of the psychoactive drug 2C-B on isolated rat aorta. Gen Pharmacol 1992, 23:1139-1142.
70. 2A receptor agonists. J Med Chem 2006, 49:5794-5803. D.E.
71. Manini A.F., Kabrhel C., Thompson T.W. Acute myocardial infarction after over-the-counter use of pseudoephedrine. Ann Emerg Med 2005, 45:213-216.
72. Martínez-Clemente J., Escubedo E., Pubill D., Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 2012, 22:231-236.
73. Mehrotra S., Gupta S., Chan K.Y., Villalón C.M., Centurión D., Saxena P.R., et al. Current and prospective pharmacological targets in relation to antimigraine action. Naunyn-Schmiedeberg's Arch Pharmacol 2008, 378:371-394.
74. Miller S.C., Waite C. Ephedrine-type alkaloid-containing dietary supplements and substance dependence. Psychosomatics 2003, 44:508-511.
75. Moghal M., Melegros L. Life threatening abdominal complications following cocaine abuse. J R Soc Med 2006, 99:51-52.
76. Monte A.P., Waldman S.R., Marona-Lewicka D., Wainscott D.B., Nelson D.L., Sanders-Bush E., et al. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem 1997, 40:2997-3008.
77. 3H]5-HT transport in mammalian cell lines. Br J Pharmacol 2007, 152:1121-1130.
78. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 2005, 5:79-86.
79. 2C receptors. J Pharmacol Exp Ther 2007, 321:1054-1061.
80. Murray B.L., Murphy C.M., Beuhler M.C. Death following recreational use of designer drug "bath salts" containing 3,4-methenedioxypyrovalerone. J Med Toxicol 2012, 8:69-75.
81. Nagai F., Nonaka R., Satoh K., Kamimura H. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007, 559:132-137.
82. 2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 2004, 104:59-81.
83. Naik S.D., Freudenberger R.D. Epherdra-associated cardiomyopathy. Ann Pharmacother 2004, 38:400-403.
84. Negus S.S., Baumann M.H., Rothman R.B., Mello N.K., Blough B.E. Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine. J Pharmacol Exp Ther 2009, 329:272-281.
85. 1A receptors: potential implications for prophylactic and acute therapy. Naunyn-Schmiedeberg's Arch Pharmacol 1997, 355:682-688.
86. 35S]GTPγS binding in rat brain membranes. Biol Pharm Bull 2007, 30:2328-2333.
87. O'Leary M.E., Hancox J.C. Role of voltage-gated sodium, potassium and calcium channels in the development of cocaine-associated cardiac arrhythmias. Br J Clin Pharmacol 2009, 69:427-442.
88. Palamar J. How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy. Health Policy 2011, 99:1-9.
89. Passie T., Halbern J.H., Stichtenoth D.O., Emrich H.K., Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 2008, 14:295-314.
90. 2-agonists in asthma treatment 1997, 1-18. Marcel Dekker, Inc., New York. R. Pauwels, P.M. O'Byrne (Eds.).
91. Prejbisz A., Lenders J.W.M., Eisenhofer G., Januszewicz A. Cardiovascular manifestations of phaeochromoctyoma. J Hypertens 2011, 29:2049-2060.
92. Prosser J.M., Nelson L.S. The toxicity of bath salts: a review of synthetic cathinones. J Med Toxicol 2011, 8:33-42.
93. Psychonaut Web Mapping Research Group Bromo-dragonfly report 2010, http://www.psychonautproject.eu/documents/reports/Bromodragonfly.pdf (Last accessed 28/04/2012).
94. Psychonaut Web Mapping Research Group Mephedrone report 2010, http://www.psychonautproject.eu/documents/reports/Mephedrone.pdf (last accessed 28/04/2012).
95. Qureshi A.I., Suri F.K., Guterman L.R., Hopkins L.N. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the third national health and nutrition survey. Circulation 2001, 103:502-506. [.r].
96. Randall M.D., Kendall D.A., O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 2004, 142:20-26.
97. Rasmussen N. Making the first anti-depressant: amphetamine in American Medicine, 1929-1950. J Hist Med Allied Sci 2006, 61:288-323.
98. Raval M.V., Gaba R.C., Brown K., Sato K.T., Eskandari M.K. Percutaneous transluminal angioplasty in the treatment of extensive LSD-induced lower extremity vasospasm refractory to pharmacologic therapy. J Vasc Interv Radiol 2008, 19:1227-1230.
99. Regan L., Mitchelson M.C., Macdonald M. Mephedrone toxicity in a Scottish emergency department. Emerg Med J 2010, 28:1055-1058.
100. Roon K.I., MaassenVanDenBrink A., Ferrari M.D., Saxena P.R. Bovine isolated middle cerebral artery contractions to antimigraine drugs. Naunyn-Schmiedeberg's Arch Pharmacol 1999, 360:591-596.
101. Ross S., Peselow E. The neurobiology of addictive disorders. Clin Neuropharmacol 2009, 32:269-276.
102. Rothman R.B., Vu N., Partilla J.S., Roth B.L., Hufeisen S.J., Compton-Toth B.A., et al. In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharm Exp Ther 2003, 307:138-145.
103. Rothman R.B., Baumann M.H. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 2002, 95:73-88.
104. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000, 102:2836-2841.
105. Samenuk D., Link M.S., Homoud M.K., Contreras R., Theohardes T.C., Wang P.J., et al. Adverse cardiovascular events temporally associated with Ma Huang, a herbal source of ephedrine. Mayo Clin Proc 2002, 77:12-16.
106. Schiff P.L. Ergot and its alkaloids. Am J Pharm Educ 2006, 70:98.
107. Schwartz B.G., Rezkella S., Kloner R.A. Cardiovascular effects of cocaine. Circulation 2010, 122:2558-2569.
108. Setola V., Hufeisen S.J., Grande-Allen K.J., Vesely I., Glennon R.A., Blough B., et al. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003, 63:1223-1229.
109. Shulgin A.T., Carter M.F. N,N-diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltrypamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun Psychopharmacol 1980, 4:363-369.
110. Siegel W. The first provocative test for coronary artery spasm at the Cleveland Clinic. Am J Cardiol 2010, 105:1198-1199.
111. Skinner M.H., Thompson D.A. Pharmacologic considerations in the treatment of substance abuse. South Med J 1992, 85:1207-1219.
112. Sogawa C., Sogawa N., Tagawa J., Fujino A., Ohyama K., Asanuma M., et al. 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin. Toxicol Lett 2007, 170:75-82.
113. Soni M.G., Carabin I.G., Griffiths J.C., Burdock G.A. Safety of Ephedra: lessons learned. Toxicol Lett 2004, 150:97-110.
114. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol 2011, 49:499-505.
115. Tanaka E., Kamata T., Katagi M., Tsuchihashi H., Honda K. A fatal poisoning with 5-methyoxy-N,N-diisopropyltryptamine, Foxy. Forensic Sci Int 2006, 163:152-154.
116. Treadwell S.D., Robinson T.G. Cocaine use and abuse. Postgrad Med J 2007, 83:389-394.
117. Upshall D.G., Wailling D.G. The determination of LSD in human plasma following oral administration. Clin Chem Acta 1972, 36:67-73.
118. Watts S.W. The love of a lifetime: 5-HT in the cardiovascular system. Am J Physiol Regul Integr Comp Physiol 2002, 296:R252-R256.
119. Westover A.N., Nakonezny P.A., Haley R.W. Acute myocardial infarction in young adults who abuse amphetamines. Drug Alcohol Depend 2008, 96:49-56.
120. Wilson J.M., McGeorge F., Smolinske S., Meatherall R. A foxy intoxication. Forensic Sci Int 2005, 148:31-36.
121. Winstock A., Mitcheson L., Marsden J. Mephedrone: still available and twice the price. Lancet 2010, 376:1537.
122. Wood D.M., Greene S.L., Dargan P.I. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 2011, 28:280-282.
123. Wood D.M., Puchnarewicz M., Johnston A., Dargan P.I. A case series of individuals with analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity. Eur J Clin Pharmacol 2011, 68:349-353.
124. Yubero-Lahoz S., Ayestas M.A., Blough B.E., Partilla J.S., Rothman R.B., de la Torre R., et al. Effects of MDMA and related analogues on plasma 5-HT: relevance to 5-HT transporters in blood and brain. Eur J Pharmacol 2011, 674:337-344.